News

STAMFORD ADVOCATE | 03.11.18

Sema4 Aims to Advance Newborn Testing With Latest Product

“Newborns in the U.S. are usually tested for about three dozen diseases. But that number only scratches the surface of potential illnesses, says genomic-testing firm Sema4. Aiming to fill the gaps between the scope of traditional tests and the thousands of disorders that can afflict young children, Stamford-based Sema4 launched last month an at-home test for 193 conditions that manifest in childhood…”
READ MORE
SEMA4 PRESS RELEASE | 02.28.18

Poll Finds Most Americans Want to Know About Their Baby’s Genetic Risk for Treatable Childhood Disorders

“Sema4 today announced the results of a public opinion poll of among more than 2,000 Americans about newborn genetic screening. According to the survey, commissioned by Sema4 and conducted online by Harris Poll, 88% of Americans say that if they were new parents and could find out just after their baby is born about their child’s genetic risk of getting a treatable early onset disease, they would want to know…”
READ MORE
GENOMEWEB | 02.12.18

Sema4 Launches Newborn Screening Targeted Sequencing Test

“Sema4, the Mount Sinai Health System spinout that launched last year, has added a sequencing-based newborn screening test to its menu that looks for 193 disorders and analyzes pharmacogenomic genes related to 38 common pediatric medications…”
READ MORE
CLINICALOMICS | 02.09.18

Sema4 Supplemental Test for Newborns Screens for 193 Diseases

“Genomic testing and health information company Sema4 has launched a newborn test that screens for 193 childhood-onset diseases and disorders with the intention of providing parents with additional information about the health of their newborn baby. Sema4 Natalis serves as an additional testing method for conditions beyond the 34 conditions on the Recommended Uniform Screening Panel (RUSP), typically screened in U.S.-based hospitals shortly after birth…”
READ MORE
HARTFORD COURANT | 02.09.18

Stamford Health Company Can Screen Newborns For 193 Conditions

“A Stamford-based health information company wants to use DNA sequencing to give parents more information from the start on their children’s health. Sema4, which spun out of New York’s Mount Sinai Health System, has developed a supplemental newborn screening test called Natalis that covers 193 childhood-onset diseases and disorders — all treatable with medication, dietary changes or other therapies, if caught early…”
READ MORE
MIT TECHNOLOGY REVIEW | 02.07.18

A New DNA Test Will Look for 190 Diseases in Your Newborn’s Genetic Code

“Using a swab of saliva from a newborn’s cheek, a new DNA test will probe the baby’s genes to search for 193 genetic diseases, like anemia, epilepsy, and metabolic disorders. The test is meant for healthy babies, as a supplement to existing screening tests…”
READ MORE
XCONOMY | 02.07.18

With New Test, Schadt’s Sema4 Aims to Broaden Scope of Newborn Screening

“Sema4, the company that computational geneticist Eric Schadt spun out of the Icahn School of Medicine at Mount Sinai last year, is making a new bet this morning. The New York and Connecticut startup is launching a diagnostic, Sema4 Natalis, meant to go well beyond the typical tests hospitals run on newborn babies to check for serious diseases…”
READ MORE
SEMA4 PRESS RELEASE | 02.07.18

Sema4 Launches Supplemental Newborn Screening Test for 190+ Childhood-Onset Diseases

“Sema4 today announced the launch of Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders so parents can gain early insight into their baby’s health. This simple genetic test can be performed at home with a gentle cheek swab…”
READ MORE
SEMA4 PRESS RELEASE | 12.18.17

Sema4 Appoints Corporate Development Executive Kareem Saad as Chief Strategy Officer

“Sema4 today announced the appointment of Kareem Saad as Chief Strategy Officer. Mr. Saad has extensive experience in the healthcare and life sciences sector, where, over the span of a twenty-year career, he has been responsible for developing and implementing strategic execution plans, managing partner businesses, and completing corporate, fundraising and business development transactions worth more than $500 million. At Sema4, he will lead a major push for corporate strategy and growth, working closely with business partners and current as well as prospective investors…”
READ MORE
SEMA4 PRESS RELEASE | 12.11.17

Researchers at Mount Sinai and Sema4 Develop Powerful New Method for Microbiome Analysis

“Scientists from the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions New York University and the University of Florida today published a report detailing their new, more accurate method for identifying individual microbial species and strains in a community. This technique has important implications for microbiome analysis, with potential long-term applications for clinical care…”
READ MORE